Q2
DXCM — Q2 2026 Financial Report Analysis
Dexcom's Q2 2026 revenue rose 13% to $1.31B (12% organic), and operating margin jumped to 24.3% from 18.4% as the 15-day G7 and factory efficiency lifted gross margin to 63.4%, despite a $45.6M inventory write-down tied mostly to retiring the G6.